Back to Search
Start Over
Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy.
- Source :
-
Advances in therapy [Adv Ther] 2024 Aug; Vol. 41 (8), pp. 3407-3418. Date of Electronic Publication: 2024 Jul 04. - Publication Year :
- 2024
-
Abstract
- Introduction: Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in the setting of real clinical practice in Italy.<br />Methods: A retrospective analysis was conducted on the administrative databases for a catchment area of about seven million health-assisted residents. Adults receiving ROS/EZE as a single-pill combination from January 2010 to June 2020 (followed up to 2021) were identified. The date of the first prescription of single-pill combination of ROS/EZE was considered as the index date. The analysis included the users of ROS/EZE as a free combination during the year before the index date. Baseline demographic and clinical characteristics were collected during the period of data availability prior to the index date. Adherence to therapy was evaluated as proportion of days covered (PDC), namely the percentage of days during which a patient had access to medication, in the 12-month interval preceding or following the index date (PDC < 25% non-adherence; PDC = 25-75% partial adherence; PDC > 75% adherence).<br />Results: A total of 1219 patients (61.1% male, aged 66.2 ± 10.4 years) were included. Cardiovascular comorbidities were found in 83.3% of them, diabetes in 26.4%, and a combination of both in 16.2%. Single-pill combination of ROS/EZE was associated with a higher proportion of adherent patients compared to free-pill combination (75.2% vs 51.8%, p < 0.001).<br />Conclusions: This real-world analysis suggested that switching from a regimen based on separate pills to one based on a single-pill combination resulted in improved adherence to ROS/EZE therapy.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Retrospective Studies
Italy
Aged
Middle Aged
Anticholesteremic Agents therapeutic use
Anticholesteremic Agents administration & dosage
Drug Therapy, Combination
Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Cardiovascular Diseases drug therapy
Rosuvastatin Calcium therapeutic use
Rosuvastatin Calcium administration & dosage
Ezetimibe therapeutic use
Medication Adherence statistics & numerical data
Drug Combinations
Subjects
Details
- Language :
- English
- ISSN :
- 1865-8652
- Volume :
- 41
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Advances in therapy
- Publication Type :
- Academic Journal
- Accession number :
- 38963586
- Full Text :
- https://doi.org/10.1007/s12325-024-02916-8